OCS Stock Overview
A clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Oculis Holding AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1,650.00 |
52 Week High | US$1,850.00 |
52 Week Low | US$1,610.00 |
Beta | 0.082 |
1 Month Change | -2.94% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -2.37% |
Recent News & Updates
Recent updates
Shareholder Returns
OCS | IS Pharmaceuticals | IS Market | |
---|---|---|---|
7D | -0.6% | 0% | 0% |
1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how OCS performed against the IS Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how OCS performed against the IS Market.
Price Volatility
OCS volatility | |
---|---|
OCS Average Weekly Movement | 3.8% |
Pharmaceuticals Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in IS Market | 0% |
10% least volatile stocks in IS Market | 0% |
Stable Share Price: OCS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OCS's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 36 | Riad Sherif | oculis.com |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Oculis Holding AG Fundamentals Summary
OCS fundamental statistics | |
---|---|
Market cap | Kr68.49b |
Earnings (TTM) | -Kr9.17b |
Revenue (TTM) | Kr136.36m |
502.3x
P/S Ratio-7.5x
P/E RatioIs OCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OCS income statement (TTM) | |
---|---|
Revenue | CHF876.00k |
Cost of Revenue | CHF33.96m |
Gross Profit | -CHF33.08m |
Other Expenses | CHF25.80m |
Earnings | -CHF58.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.41 |
Gross Margin | -3,776.14% |
Net Profit Margin | -6,721.46% |
Debt/Equity Ratio | 0% |
How did OCS perform over the long term?
See historical performance and comparison